EN | RU
EN | RU

Help Support

Back

Effectiveness and safety of tocilizumab therapy for moderate or severe COVID-19

Effectiveness and safety of tocilizumab therapy for moderate or severe COVID-19 Effectiveness and safety of tocilizumab therapy for moderate or severe COVID-19
Effectiveness and safety of tocilizumab therapy for moderate or severe COVID-19 Effectiveness and safety of tocilizumab therapy for moderate or severe COVID-19

To assess the safety and effectiveness of tocilizumab in COVID-19 patients and identify the patients with COVID-19 who may benefit from this therapy.

See All

Key take away

The use of tocilizumab had been known to weaken the "cytokine storm" in patients with COVID-19. This anti–interleukin-6 receptor monoclonal antibody can be suggested for better disease management in COVID-19 patients with bilateral pulmonary lesions and elevated IL-6 levels, as deduced from this randomized, controlled, open-label multicenter trial.

Background

To assess the safety and effectiveness of tocilizumab in COVID-19 patients and identify the patients with COVID-19 who may benefit from this therapy.

Method

Sixty-five patients were randomized to receive either tocilizumab along with standard care (33 patients) or just standard care (32 patients). The cure rate, variations in oxygen saturation, and inflammation biomarkers were studied.

Result

The patients in the tocilizumab group had higher cure rate (not statistically significant) as compared to the control group. Tocilizumab group had improved hypoxia starting from day 4 and statistically significant from day 12.

In patients with moderate COVID-19 severity having bilateral pulmonary lesions, hypoxia improved quicker following the use of tocilizumab, and less patients required an increase of inhaled oxygen concentration than controls. Although no severe adverse events were reported, but patients in the tocilizumab group had mild, short-term adverse events.

Conclusion

The use of tocilizumab therapy was found to be safe and improved hypoxia in COVID-19 patients. It had no significant effect on the time required for negative viral load.

Source:

Frontiers of Medicine

Article:

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Authors:

Dongsheng Wang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: